Cargando…
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. T...
Autores principales: | Gilaberte Reyzabal, Sergio, Isenberg, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149152/ https://www.ncbi.nlm.nih.gov/pubmed/35652065 http://dx.doi.org/10.3389/fmed.2022.882891 |
Ejemplares similares
-
Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019) -
Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
por: Wincup, Chris, et al.
Publicado: (2019) -
Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015) -
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples
por: Reddy, Venkat, et al.
Publicado: (2017) -
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
por: Vallerskog, Therese, et al.
Publicado: (2006)